← Library
Prescription-only medicine. This page is educational information only. Do not use without a licensed prescriber.
IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Angiotensin II

FDA approved · Rx

Vasoconstrictor peptide hormone

Also known as: Giapreza, Human angiotensin II, Angiotensin II (human), Ang II, 5-L-Isoleucineangiotensin II, 5-Isoleucine-angiotensin II, Angiotensin II (mouse), Asp-Arg-Val-Tyr-Ile-His-Pro-Phe

Evidence score
95/ 100
Strong evidence

Strong, human-grade evidence

  • Regulatory standing. FDA-approved prescription medicine
  • Human trials. Backed by controlled human studies
  • Registered human trials. 343 registered studies on ClinicalTrials.gov, most advanced Phase 4
  • 2 cited sources. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Angiotensin II is a naturally occurring eight amino acid peptide hormone that is part of the body's renin-angiotensin-aldosterone system. It raises blood pressure mainly by binding AT1 receptors, which narrows blood vessels and promotes aldosterone and vasopressin release. A synthetic version is sold as the prescription drug Giapreza.

What the evidence shows

Automatic summaryHuman trials

Giapreza is FDA approved for increasing blood pressure in adults with septic or other distributive shock, given in hospital settings, based on randomized trial data. It is heavily studied, with hundreds of registered human trials, but uses outside its approved indication are less established.

Key facts

Molecular formula
C50H71N13O12
Molecular weight
1046.2 g/mol
FDA approval
Confirmed on openFDA

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

343registered studies
Phase 4most advanced phase
55completed (sample)
11recruiting (sample)

Angiotensin II Pathway and Postoperative Hypoxemia

CompletedNCT05055570

Angiotensin-II Blockade in Mitral Regurgitation

Phase 4CompletedNCT00587470

Angiotensin II and Chronic Inflammation in Persistent Microvascular Dysfunction Following Preeclampsia

Early Phase 1CompletedNCT03482440

Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer

Phase 2CompletedNCT00771810

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

60,565papers referencing Angiotensin II

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

N Engl J Med2001

Liver fibrosis.

J Clin Invest2005

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

N Engl J Med2001

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Lancet2002

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.